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The development of locoregional recurrence is the main reason for treatment failure in head and neck
squamous cell carcinomas (HNSCC) and the remaining of tumor cells in surgical margins is associatedwith
recurrence. Surgical margins are considered negative based on histologic assessment of the pathological
specimen. However, this method lacks sensitivity in identifying cells that already started malignant trans-
formation but have not yet developed a pathologic phenotype.We investigated the usefulness of assessing
the expression of PTHLH, EPCAM,MMP9, LGALS1 andMET for the detection of molecular alterations in his-
tologically negative surgical margins and determine the correlation of these tumor-related alterations
with clinical and prognostic parameters. Differential gene expression was determined by quantitative
RT–PCR analyses in normal mucosa, HNSCC and negative margin samples. Thirty-eight percent of the his-
tologically negative surgical margins examined were margin-positive for overexpression of at least one of
the genes evaluated. Moreover, MMP9 and PTHLH overexpression in the surgical margins was associated
with the development of second primary tumors (p = 0.002) and lower rates of local control (log rank test
p = 0.022; HR = 4.186; p = 0.035), respectively. These ﬁndings demonstrate that the overexpression of
tumor-related genes in histologically negative surgical margins is a frequent event. The use of qRT–PCR
may be an useful tool in detecting actually negative HNSCC surgical margins and the overexpression of
speciﬁc genes in thesemargins could be helpful in the identiﬁcation of patients with a higher risk of devel-
oping second primary tumors and local recurrences, thus aiding the surgeon in the delineation of the
HNSCC resection extent and helping in the planning of adjuvant therapy.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Head and neck cancer is the eighth most common cancer world-
wide, with approximately 650,000 new cases per year1 and more
than 90% being squamous cell carcinomas (HNSCC). Despite differ-
ent strategies used in the treatment of HNSCC cases, a signiﬁcant
percentage of advanced patients still have a poor prognosis, with
a high percentage of locoregional and distant recurrences.2,3 Note-
worthy, the great genetic and biological heterogeneity of HNSCC
makes difﬁcult the comprehension of the molecular carcinogenesis
process of these tumors and the development of new therapeutic
strategies.
The presence of microscopic tumor in the surgical margins is
associated with the high rate of HNSCC relapse and shorter overall
survival.4 Therefore, obtaining negative surgical margins is of par-x: +55 11 5571 8806.
tore).
evier OA license.amount importance in reducing these recurrence rates. The extent
of tumor surgical resection is conventionally determined during
surgery by the surgeon’s gross assessment complemented by an
intraoperative examination of the margins based in histologic
hematoxylin–eosin (H&E) diagnosis of frozen sections. In spite of
the high accuracy ratio reported for this histologic examination
(>95%)5–8 the elevated rate of treatment failure (around 30%) in pa-
tients with histologically negative margins raises concern about
the sensitivity of this method.9,10
Therefore, the intraoperative diagnosis of histologically nega-
tive margins, although extremely accurate, does not eliminate
the possibility of the presence of tumor cells contributing to lo-
cal relapses. Taking into account that genetic alterations precede
phenotypic changes of the epithelium, molecular assessment of
surgical margins could constitute a more sensitive approach to
detect the presence of malignant transformed cells in histologi-
cally negative surgical margins. Attempts using different
molecular strategies have already been performed (i.e., TP53
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microsatellite instability and gene-promoter hypermethylation
proﬁle).11–22
Recent studies are focused on identifying molecular factors that
may provide useful prognostic information and inﬂuence the clin-
ical management of HNSCC patients. Ferris et al.23 showed that
PTHLH and EPCAM expression was able to discriminate between
positive and benign lymph nodes with a high accuracy. Moreover,
the IHC detection of MMP9 in surgical margins has showed a posi-
tive association with the risk of relapse in HNSCC patients.13,14
However, a signiﬁcant limitation of IHC evaluations is the long
time required to carry out the examination, rendering its use dur-
ing surgery. Besides, microarray analyses have found LGALS1 and
MET overexpressed in HNSCC samples as compared with normal
mucosa.24,25
Previous studies have already supported the theory of ﬁeld
cancerization, which refers to the presence of malignant or prema-
lignant changes in the entire ﬁeld of apparently normal tissue adja-
cent to the tumor in response to a carcinogen exposition.26 Thus,
the goal of this study was to evaluate the ability of PTHLH, EPCAM,
MMP9, LGALS1 and MET expression in identifying tumor-related
alterations in histologically negative surgical margins. In this
way, we hypothesize that the expression proﬁle of these genes in
histologically negative margins could act as a more sensitive and
useful marker for the detection of molecular alterations associated
with local disease control in HNSCC patients.Materials and methods
Patients
This retrospective study involved tissue specimens from 55
HNSCC patients who underwent tumor resection between 2000–
2008 at A.C. Camargo Hospital and Barretos Cancer Hospital. Only
patients diagnosed with primary HNSCC, with surgery as primary
curative treatment and with surgical margins samples available
were included. Histologically negative surgical margins were avail-
able from all 55 patients, while primary HNSCC samples were ob-
tained from a subset of 23 patients.
Surgical margin samples comprised mucosa with a clinically
normal appearance taken at surgery at least 1 cm from the tumor
edge and reported as ‘‘histologically negative’’ after routine intra-
operative histologic examination. Prior to RNA extraction and after
removal of tumor from the surgical specimen, all remaining lateral
margins were processed as a pool and hematoxylin–eosin stained
slides were re-evaluated by a senior pathologist in order to conﬁrm
the diagnosis. Only surgical margins classiﬁed as histologically
negative and without the presence of premalignant lesions such
as dysplasia, were included in the study. Additionally, 25 oral mu-
cosa tissue samples from healthy donors undergoing odontological
and pre-prosthetic surgeries were used as normal controls. In-
formed consent was obtained from each individual prior to tissue
collection and the study protocol was approved by A.C. Camargo
Hospital and Barretos Cancer Hospital Ethic Committees and per-
formed in accordance with the ethical guidelines of the 1975 Dec-
laration of Helsinki.Gene expression quantiﬁcation by Real-time RT–PCR (RT–qPCR)
Total RNA was isolated from approximately 0.5 cm3 of frozen
tissue samples using Trizol reagent (Invitrogen, Frederick, MD)
and 2 lg were reverse transcribed using SuperScripIII First Strand
Synthesis Kit (Invitrogen, Frederick, MD) according to manufac-
turer’s recommendations. Each cDNA mixture was diluted 10-fold
before use.PCR ampliﬁcation was performed in an ABI 7500 Fast Sequence
Detection System using the TaqMan system (Applied Biosystems,
Foster City, CA). Primers and probes were obtained from the Inven-
toried TaqMan Gene Expression Assays (Applied Biosystems, Foster
City, CA). PCR reaction conditions can be provided if requested.
The relative gene expression level was calculated using the
mathematical equation 2(DDCt).27 Each sample data was normal-
ized on the basis of the average expression of two reference genes
(HPRT1 and RPLPO) selected by a NormFinder analysis28 (data not
shown). The average expression value obtained from 10 normal
oral mucosa samples was used as calibrator. Additional 15 normal
oral mucosa samples were used to calculate speciﬁcity levels. Final
results were expressed as n-fold differences in gene expression be-
tween the evaluated sample and the calibrator sample.
Statistical analysis
Sensitivity and speciﬁcity of each individual gene in distin-
guishing HNSCC samples from normal controls were calculated. A
Receiver Operating Characteristic (ROC) curve was constructed
with the expression level of each gene in the HNSCC samples and
in 15 normal controls. The area under the receiver operator charac-
teristic (AUC) identiﬁed optimal sensitivity and speciﬁcity levels to
distinguish HNSCC patients from healthy individuals, allowing the
deﬁnition of cut-off values for each gene.
The association between the clinical variables and molecular
data was evaluated using Chi-square or Fisher’s exact tests. The ef-
fects of the molecular markers and clinical variables on overall, lo-
cal recurrence-free and locoregional recurrence-free survival, and
potential ﬁeld lesions (local, regional and second primary tumors
in the UADT) were estimated by Kaplan–Meier method and com-
pared by the log-rank test. Cox proportional hazard regression
analysis was performed to estimate the hazard ratios (HR) for clin-
ical and molecular variables. All statistical analysis was performed
using the statistical software SPSS 17.0 for Windows and a level of
signiﬁcance of p < 0.05 was adopted.Results
Follow-up and characteristics of the patients
Clinical and pathological data of the 55 HNSCC patients enrolled
in this study are presented in Table 1. The mean follow-up was
30.6 months (median = 20.9 months; range 0.43–98.13 months).
Mean interval from diagnosis to recurrence was 12.2 months
(range 5–24 months). Treatment failure was observed in 34.5% of
the cases (19/55): 11 patients (20.0%) showed local recurrence,
15 (27.3%) locoregional recurrence and 4 (7.3%) patients developed
second primary tumors (SPT) in the upper aerodigestive tract
(lung, tongue, esophagus and lip) deﬁned according to the criteria
proposed by Warren and Gates.29 Therefore, 19 (34.5%) patients
developed potential ﬁeld lesions (local or regional recurrences
and SPT in the UADT).
Molecular analysis of primary tumors and surgical margins
The expression levels of 5 genes, PTHLH, EPCAM, MMP9, LGALS1
and MET, were assessed by qRT-PCR assays.
In the ﬁrst series, we evaluated the feasibility of these genes in
distinguishing normal and tumor samples. The sensitivity and
speciﬁcity levels were calculated based on the differential frequen-
cies of overexpression in tumor and normal mucosa samples in
comparison to a set of 10 normal mucosa samples used as calibra-
tor. ROC curve analyses and AUC results aided to deﬁne cut-off lev-
els as n-fold values above the maximum level of gene expression in
Table 1
Clinical and pathological data of the patients enrolled in the study.
Characteristic Number of cases (%) MMP9 EPCAM PTHLH
Negative Positive p Negative Positive p Negative Positive p
Total patients 55 (100.0)
Age
Mean, median, range 58.25, 59.0, 28–85 years
<60 years 31 (56.4) 26 (83.9) 5 (16.1) 0.136 28 (90.3) 3 (9.7) 0.534 30 (96.8) 1 (3.2) 0.107
>60 years 24 (43.6) 16 (66.7) 8 (33.3) 21 (87.5) 3 (12.5) 20 (83.3) 4 (16.7)
Tobacco consumption
No 12 (21.8) 8 (66.7) 4 (33.3) 0.296 11 (91.7) 1 (8.3) 0.609 11 (91.7) 1 (8.3)
Yes 43 (78.2) 34 (79.1) 9 (20.9) 38 (88.4) 5 (11.6) 39 (90.7) 4 (9.3) 0.702
Alcohol consumption
No 18 (32.7) 13 (72.2) 5 (27.8) 0.426 16 (88.90 2 (11.1) 0.649 17 (94.4) 1 (5.6) 0.467
Yes 37 (67.3) 29 (78.4) 8 (21.6) 33 (89.2) 4 (10.8) 33 (89.2) 4 (10.8)
Clinical nodal status
N- 24 (43.6) 17 (70.8) 7 (29.2) 0.272 20 (83.3) 4 (16.7) 0.234 22 (91.7) 2 (8.3) 0.607
N+ 30 (54.5) 25 (83.3) 5 (16.7) 28 (93.3) 2 (6.7) 27 (90.0) 3 (10.0)
Unknown 1 (1.9)
Clinical tumor status
T1–T2 26 (47.2) 21 (80.8) 5 (19.2) 0.61 25 (96.2) 1 (3.8) 0.114 25 (96.2) 1 (3.8) 0.199
T3–T4 28 (50.9) 21 (75.0) 7 (15.0) 23 (82.1) 5 (17.9) 24 (85.7) 4 (14.3)
Unknown 1 (1.8)
Clinical TNM stage*
Initial (I/II) 16 (29.1) 11 (68.8) 5 (31.3) 0.245 15 (93.8) 1 (6.3) 0.418 15 (93.8) 1 (6.3) 0.532
Advanced (III/IV) 38 (69.1) 31 (81.6) 7 (18.4) 33 (86.8) 5 (13.2) 34 (89.5) 4 (10.5)
Not available 1 (1.8)
Primary tumor site
Oropharynx 6 (11.0) 5 (83.3) 1 (16.7) 0.583 5 (83.3) 1 (16.7) 0.023 6 (100) 0 (0) 0.201
Oral cavity 41 (74.5) 32 (78) 9 (22) 39 (95.1) 2 (4.9) 38 (92.7) 3 (7.3)
Larinx 8 (14.5) 5 (62.5) 3 (37.5) 5 (62.5) 3 (37.5) 6 (75) 2 (25)
Treatment
Surgery + radiotherapy 35 (65.6) 27 (77.1) 8 (22.9) 0.553 30 (85.7) 5 (14.3) 0.28 31 (88.6) 4 911.4) 0.394
Surgery only 20 (36.4) 15 (75.0) 5 (25.0) 19 (95.0) 1 (5.0) 19 (95.0) 1 (5.0)
Vascular embolization
Negative 43 (78.2) 33 (76.7) 10 (23.3) 0.529 38 (88.4) 5 (11.6) 0.646 41 (95.3) 2 (4.7) 0.052
Positive 11 (20) 8 972.7) 3 (27.3) 10 (90.9) 1 (9.1) 8 (72.7) 3 (27.3)
Unknown 3 (5.4)
Perineural invasion
No 30 (54.5) 25 (83.3) 5 (16.7) 0.2 26 (86.7) 4 (13.3) 0.494 29 (96.7) 1 (3.3) 0.095
Present 22 (40) 15 (68.2) 7 (31.8) 20 (90.9) 2 (9.1) 18 (81.8) 4 (18.2)
Not available 3 (5.5)
Second primary tumor
No 51 (92.7) 42 (82.4) 9 (17.6) 0.002 45 (88.2) 6 (11.8) 0.621 46 (90.2) 5 (9.8) 0.675
Yes 4 (7.3) 0 (0) 4 (100) 4 (100) 0 (0) 4 (100) 0 (0)
* Clinical stage according to TNM Classiﬁcation of Malignant Tumours – 6th ed.
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Table 2
Capability of the gene expression to discriminate HNSCC and historically free surgical margins samples from healthy oral mucosa.
Gene AUC Cut-off  HNSCC samples Healthy oral mucosa Surgical margins
Sensitivity# % (95% CI) Speciﬁcity

% (95% CI) Expression frequency§ % (95% CI)
MMP9 1 10 91 (71.9–98.9) 100 (78.2–100.0) 23.6 (13.23–37.02)
PTHLH 0.87 5 74 (51.6–89.8) 93 (68.0–99.8) 10.9 (4.11–22.45)
EPCAM 0.6 10 30 (13.2–52.9) 100 (78.2–100.0) 9.1 (3.02–19.95)
LGALS1 0.83 3 83 (61.2–95.5) 73 (44.9–92.2) NE
MET 0.84 3 48 (26.8–69.4) 86 (59.5–98.3) NE
 Cut-off value adopted to consider a positive gene expression.
# Evaluated in 23 tumor samples.
 Evaluated in 15 healthy oral mucosa.
§ Evaluated in 55 surgical margin samples, NE = not evaluated.
Figure 1 Expression levels of the ﬁve selected genes in 15 healthy oral mucosa, 23 HNSCC patients and 55 histologically negative surgical margins.
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Figure 2 Receiver operating characteristic (ROC) curve obtained for MMP9 over-
expression in histologically negative surgical margins according to development of
second primary tumors.
Table 3
Results of univariate analysis of selected prognostic factors for overall survival.
Characteristic Number
of cases
Number
of deaths
5-year over
survival
Tobacco consumption
No 12 2 76.2
Yes 53 22 31.7
Alcohol consumption
No 18 7 37.5
Yes 37 17 42.3
Clinical nodal status
N 24 7 53.8
N+ 30 17 26
Unknown 1
Clinical tumor status
T1–T2 26 6 69.8
T3–T4 28 18 19.6
Unknown 1
Clinical TNM stage*
Initial (I/II) 16 2 81.7
Advanced (III/IV) 38 22 25.4
Unknown 1
Primary tumor site
Oropharynx 6 5 0
Oral cavity 41 15 51.3
Larynx 8 4 25
Treatment
Surgery + radiotherapy 35 19 34
Surgery only 20 5 52.4
Vascular embolization
Negative 43 15 46.3
Positive 11 8 27.3
Unknown 3
Perineural invasion
Negative 30 8 48.1
Positive 22 14 30.2
Unknown 2
MMP9 overexpression in surgical margins
Negative 42 17 39.3
Positive 13 7 32.7
EPCAM overexpression in surgical margins
Negative 49 21 41.5
Positive 6 2 0
PTHLH overexpression in surgical margins
Negative 50 21 40
Positive 5 3 25
* Clinical stage according to TNM Classiﬁcation of Malignant Tumours – 6th ed.
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speciﬁcity and sensitivity rates and maximize the capacity of dis-
tinction between HNSCC and healthy subjects (Fig. S1). Hence,
for MMP9 and EPCAM a 10X cut-off was adopted, for PTHLH a
cut-off of 5X while for MET and LGALS1 a 3X cut-off was used
(Table 2). To be considered overexpressed, the gene expression
level should be higher than the cut-off value established for each
gene.
MMP9 (91%), LGALS1 (83%), PTHLH (74%), MET (48%) and EPCAM
(30%) were frequently found overexpressed in the 23 HNSCC sam-
ples (high sensitivity). MMP9, PTHLH and EPCAM were rarely over-
expressed in the 15 healthy oral mucosa samples (0%; 7% and 0%,
respectively), conﬁrming their overexpression as cancer-associated
(high speciﬁcity). On the other hand, MET and LGALS1 were found
overexpressed in 14% and 27%, respectively of the normal controls,
suggesting a lack of speciﬁcity (Fig. 1; Table 2), and were excluded
from further analyses.
Therefore, based on the high speciﬁcity and sensitivity presented
byMMP9, EPCAM and PTHLH, we further investigated the expression
of these genes in 55 histologically negative surgical margins. Even
though all surgical margins examined were diagnosed as histologi-
cally negative, 36.4% (20/55; 95% CI = 23.81–50.44) showed overex-
pression of at least one of these 3 genes.MMP9was overexpressed inall P value
(log-rank)
Hazard ratio for
death (95% CI)
P value (Cox)
Reference
0.073 3.469 (0.814–14.773) 0.092
Reference
0.599 1.266 (0.524–3.061) 0.6
Reference
0.04 2.488 (1.016–6.096) 0.046
Reference
0.009 3.249 (1.284–8.224) 0.013
Reference
0.009 5.543 (1.297–23.687) 0.021
Reference
0.268 (0.102–0.802) 0.017
0.041 0.428 (0.112–1.635) 0.215
Reference
0.231 0.551 (0.204–1.483) 0.238
Reference
0.033 2.474 (1.044–5.862) 0.04
Reference
0.02 2.690 (1.126–6.424) 0.026
Reference
0.293 1.6 (0.6661–3.871) 0.297
Reference
0.439 1.615 (0.474–5.501) 0.443
Reference
0.407 1.664 (0.493–5.619) 0.412
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and PTHLH in 9.1% (5/55) (Fig. 1; Table 2).Expression proﬁle and clinical data correlations
The expression proﬁle of the 3 selected genes (MMP9, EPCAM
and PTHLH) in histologically negative surgical margins was ana-
lyzed for potential correlations with patients’ clinicopathological
parameters.
There was no association between the overexpression of PTHLH
and EPCAM in the histologically negative surgical margins and rele-
vant patient features (Table 1). Besides that, MMP9 overexpression
in the surgical margins was correlated with the development of
SPT (p = 0.002) (Table 1) with high sensitivity, speciﬁcity and accu-
racy, 100% (4/4; 95% CI = 39.77–100.00), 82.3% (42/51; 95%
CI = 69.13–91.59) and 83.6% (46/51; 95% CI = 71.19–92.23), respec-
tively. ROC curve analysis showed an area under the curve of 0.912Table 4
Results of univariate analysis of selected prognostic factors for local recurrence-free survi
Characteristic Number
of cases
Number of local
recurrences
5-Year local
recurrence-free
survival
Tobacco consumption
No 12 1 90
Yes 43 10 67.3
Unknown 1 0
Alcohol consumption
No 18 4 69.2
Yes 37 7 74.3
Unknown 1 0
Clinical nodal status
N- 24 4 78.4
N+ 30 7 68.2
Unknown 1 0
Clinical tumor status
T1–T2 26 2 87.7
T3–T4 28 9 58.9
Unknown 1 0
Clinical TNM stage*
Initial (I/II) 16 1 88.9
Advanced (III/IV) 38 10 66.6
Unknown 1 0
Primary tumor site
Oropharynx 6 1 75
Oral cavity 41 8 73.1
Larynx 8 2 68.6
Treatment
Surgery + radiotherapy 35 10 68
Surgery only 20 1 88.9
Vascular embolization
Negative 43 7 78.6
Positive 11 4 50
Unknown 3 0
Perineural invasion
Negative 30 2 88.5
Positive 22 9 47.1
Unknown 5 0
MMP9 overexpression in surgical margins
Negative 46 9 71.5
Positive 14 2 78.8
EPCAM overexpression in surgical margins
Negative 49 9 74.1
Positive 6 2 62.5
PTHLH overexpression in surgical margins
Negative 50 8 78.3
Positive 5 3 25
* Clinical stage according to TNM Classiﬁcation of Malignant Tumours – 6th ed.(95% CI = 82.9–99.4) (Fig. 2), evidencingMMP9 as a potentialmarker
for the diagnosis of patients at risk for developing SPT.
Nineteen (34.5%) of the HNSCC patients included in this study
died of cancer and the 5-year overall survival was 46.0%. Kaplan–
Meier and Cox proportional hazard regression analyses were per-
formed to estimate the effects of conventional prognostic factors
and molecular markers on overall and local recurrence-free sur-
vival (Table 3 and Table 4), locoregional recurrence-free survival
and potential ﬁeld lesions (Table S1 and Table S2).
As expected, well known clinical prognostic factors as clinically
positive lymphnodes (p = 0.04), T3–T4 tumors (p = 0.009), advanced
tumors (p = 0.009), vascular embolization (p = 0.033), and perineu-
ral invasion (p = 0.02) were signiﬁcantly associated with reduced
OS (Table 3). No association was found between expression of the
investigated genes in the surgicalmargins andpatients’ OS (Table 3).
T3–T4 tumors (p = 0.024), perineural invasion (p = 0.002) and PTHLH
overexpression (p = 0.022) were signiﬁcantly associated with
reduced local recurrence-free survival (Fig. 3; Table 4). Patientsval.
P value (log-rank) Hazard Ratio for
local recurrence (95% CI)
P value (Cox)
Reference
0.251 3.133 (0.400–24.533) 0.277
Reference
0.985 1.012 (0.296–3.459) 0.985
Reference
0.503 1.521 (0.442–5.231) 0.506
Reference
0.024 4.959 (1.067–23.042) 0.041
Reference
0.094 4.905 (0.626–38.434) 0.13
Reference
0.790 (0.098–6.350) 0.825
0.783 1.357 (0.122–15.032) 0.804
Reference
0.13 0.233 (0.030–1.823) 0.233
Reference
0.149 2.404 (0.702–8.230) 0.162
Reference
0.002 7.976 (1.720–36.983) 0.008
Reference
0.783 0.806 (0.174–3.741) 0.783
Reference
0.329 2.111 (0.455–9.798) 0.34
Reference
0.022 4.186 (1.104–15.877) 0.035
Figure 3 Kaplan–Meier curve comparing the probability of local recurrence-free survival in patients with positive or negative overexpression of PTHLH in histologically
negative surgical margins (5-years local recurrence-free survival: 79.3% vs. 25.0%, respectively; p = 0.022).
Table 5
Results of multivariate analysis of selected prognostic factors for local recurrence-free survival and overall survival.
Characteristic Hazard ratio for local
recurrence (95% CI)
P value (Cox) Hazard ratio for death
(95% CI)
P value (Cox)
Clinical tumor status
T3–T4 12.058 (2.324–62.561) 0.003 4.834 (1.691–13.817) 0.003
Perineural invasion
Present 8.478 (1.542–46.609) 0.014 3.650 (1.455–9.156) 0.006
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prognosis and had a signiﬁcantly higher risk of developing local
recurrence (HR = 4.186; 95% CI = 1.104–15.877; p = 0.035).
The multivariate Cox regression analysis showed signiﬁcant dif-
ference in overall survival and local recurrence-free survival by
clinical features well established as poor prognostic factors: clini-
cal tumor status (p = 0.003 and p = 0.003) and perineural invasion
(p = 0.006 and p = 0.014) (Table 5). For locoregional recurrence,
perineural invasion (p = 0.012) was signiﬁcantly relevant and vas-
cular embolization (p = 0.008) and perineural invasion (p = 0.033)
were associated with potential ﬁeld lesions (Table S3). In this anal-
ysis, no signiﬁcant associations were observed between clinical
features and overexpression of the genes tested, probably due to
the small sample size analyzed in the study.
Discussion
Surgical margin status is described as an important prognostic
factor associated with high risk of local relapses and decrease in
survival rates for HNSCC patients.4,30 For this reason, the histologic
assessment of HNSCC surgical margins by the pathologist at the
time of surgery plays an important role in the success of patient
treatment. Unfortunately, local recurrence occurs in around 20%
of the patients with histologically negative margins.4,8–10 One
explanation for this resides in the fact that intraoperative histo-
logic evaluation of the mucosa cannot detect molecular alterationsthat do not involve phenotypic changes in the cells but set them up
in the tumorigenesis track.
In this study we selected 5 genes to have their expression eval-
uated in HNSCC, histologically normal surgical margins and
healthy oral mucosa samples. All genes selected have been previ-
ously found speciﬁcally overexpressed in HNSCC. However, no
study has been conducted, as of now, to evaluate them as potential
markers for detection of molecular changes in histologically nega-
tive surgical margins and as putative predictors of local failure in
HNSCC cases.
Although all patients included in this study showed histologi-
cally negative margins, 20% (11/55) presented local relapse, sug-
gesting that molecular changes not detected by standard
microscopic analysis, could be a cause of malignant transformation
and the poor outcome. This ﬁnding is in accordance with the
hypothesis introduced by Slaughter et al.26 about a residual ‘‘al-
tered ﬁeld’’ in the area adjacent to the tumor that could be the
leading cause of treatment failure due to a high propensity to de-
velop local recurrences and second primary tumors in the head
and neck after treatment.
According to our results, 36.4% of the histologically negative
margins harbored overexpression of at least one of the 3 selected
genes, MMP9, EPCAM, and PTHLH.
EPCAM (epithelial cell adhesion molecule) encodes an antigen
associated with carcinoma that is located in the cell membrane
and acts as a cell adhesion molecule. Andratschke et al.32 demon-
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expressed in the HNSCC surgical margins, but the correlation with
clinical data was not assessed. In the present study, no signiﬁcant
association was observed between the expression of this gene in
the histologically negative surgical margins and relevant patient
features.
PTHLH (parathyroid hormone-like hormone), also known as
PTHrP, regulates endochondral bone development and epithelial-
mesenchymal interactions during the formation of mammary
glands and teeth. In breast cancer, the increased expression of
PTHLH receptors is associated with proliferation, invasion and in-
crease of intracellular cyclic AMP levels.33,34 In HNSCC, this gene
acts as a mediator of epidermal growth factor receptor (EGFR)
and seems to be associated with cell growth and invasive activ-
ity.35 However, Dunne et al.36 failed to ﬁnd any correlation be-
tween the presence of PTHLH and the pattern of tumor invasion.
Our results show that the overexpression of this gene in the histo-
logically negative surgical margins was signiﬁcantly correlated
with reduced local recurrence-free survival and an increased risk
to develop local recurrences.
Another common reason for treatment failure in HNSCC is the
development of second primary tumors (SPT).37 Until recently, it
was thought that development of SPT represented progression of
multiple separate genetically altered mucosal foci. However, re-
cent studies have been reporting that at least a proportion of
these SPT arise from residual portions of a single contiguous pre-
neoplastic ﬁeld after the complete resection of the index tumor.
According to them, a stem cell acquires genetic alterations and
forms a patch with genetically altered daughter cells. As a result
of subsequent genetic alterations, the stem cell escapes normal
growth control, gains growth advantage, and develops into an
expanding clone. The lesion laterally displaces the normal epithe-
lium and additional genetic hits give rise to various subclones
within the ﬁeld. Different clones diverge at a certain point with
respect to genetic alterations but do share a common clonal ori-
gin, and as a result of the process of clonal divergence and selec-
tion, eventually a subclone evolves into invasive cancer.39 Our
results suggest that one of these genetic alterations could be
the aberrant expression of metalloproteinase-9 (MMP9) gene. Dif-
ferent studies have already reported the overexpression of this
protein in HNSCC tumor samples40,41 and a signiﬁcant correlation
with regional recurrence and distant metastasis.42 Jordan et al.43
demonstrated that, after a 7-year follow-up, several cases of dys-
plasia with higher MMP9 expression progressed to HNSCC. We
found MMP9 overexpressed in 23.6% of the histologically negative
surgical margins and this was associated with the development of
SPT (p = 0.002). AUC analyses also showed that this marker has a
high accuracy as a diagnostic test for evaluation of the risk for
SPT development. MMP9 encodes a gelatinase that degrades type
IV collagen, the major constituent of basement membrane. The
lateral spread of clones from malignant tumors involves the
occurrence of multiple factors necessary for cell motility to pen-
etrate the extracellular matrix.44 Thus, the involvement of this
protein in the process of transformation of precancerous lesions
in invasive tumors and its role in the degradation of extracellular
matrix may explain the results of the association between MMP9
overexpression and the development of SPT.
In summary, our results showed that MMP9, EPCAM, and PTHLH
are frequently and speciﬁcally overexpressed in histologically neg-
ative margins of resected HNSCC. In spite of the small number of
samples evaluated, we demonstrated that the overexpression of
PTHLH and MMP9 in histologically negative HNSCC margins is sig-
niﬁcantly correlated to a high risk of local failure and development
of SPT. for the ﬁrst time, we report a signiﬁcant association be-
tween the expression of MMP9 in histologically negative surgical
margins of HNSCC cases and the development of SPT and thatthe overexpression of PTHLH in histologically negative margins
contributes to a reduced local recurrence-free survival. Based in
these results, we may speculate that the expression of these genes
in HNSCC surgical margins, diagnosed as tumor-free by conven-
tional histopatologic analyses, could be a helpful biomarker to
identify subjects at risk of new neoplastic evolution. Further vali-
dation of these results requires studies with larger patient groups
and longer follow-up period, but by achieving a good predictive
negative value, this qRT–PCR approach could constitute an alterna-
tive tool to guide the surgeon in the delineation of the HNSCC
resection extent, in the adoption of a more intensive surveillance
during follow-up and help in the planning of adjuvant therapy. Fi-
nally, it must be stressed that histopathological examination re-
mains irreplaceable in clinical practice, allowing the detection of
histologically negative surgical margins during surgery (by H&E
examination). Hence, if qRT–PCR analysis of surgical margins is
to be used in clinical practice, it should take part in a multimodal-
ity diagnostic protocol.
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